Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

BACKGROUND: Selective BCL2 inhibition with venetoclax has substantial activity in patients with relapsed or refractory chronic lymphocytic leukaemia. Combination therapy with rituximab enhanced activity in preclinical models. The aim of this study was to assess the safety, pharmacokinetics, and acti...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Lancet Oncol
Hlavní autoři: Seymour, John F, Ma, Shuo, Brander, Danielle M, Choi, Michael Y, Barrientos, Jacqueline, Davids, Matthew S, Anderson, Mary Ann, Beaven, Anne W, Rosen, Steven T, Tam, Constantine S, Prine, Betty, Agarwal, Suresh K, Munasinghe, Wijith, Zhu, Ming, Lash, L Leanne, Desai, Monali, Cerri, Elisa, Verdugo, Maria, Kim, Su Young, Humerickhouse, Rod A, Gordon, Gary B, Kipps, Thomas J, Roberts, Andrew W
Médium: Artigo
Jazyk:Inglês
Vydáno: 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5316338/
https://ncbi.nlm.nih.gov/pubmed/28089635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30012-8
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky